Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors

被引：5

作者：

Jing, Yuling ^{[1
]}

Yang, Ruixue ^{[1
]}

Chen, Wen ^{[1
]}

Ye, Qiang ^{[1
]}

机构：

[1] Southwest Med Univ, Affiliated Hosp, Dept Cardiol, Luzhou, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2022年 / 13卷

关键词：

arrhythmia; SGLT2I; cardiac electrical remodeling; mitochondrial dysfunction; oxidative stress; cardiac structural remodeling; inflammation; MITOCHONDRIAL PERMEABILITY TRANSITION; ATRIAL-FIBRILLATION; SGLT2; INHIBITOR; NA+/H+ EXCHANGER; CARDIAC FIBROSIS; HEART-FAILURE; GAP-JUNCTION; MOUSE MODEL; DELAYED AFTERDEPOLARIZATIONS; VENTRICULAR-REPOLARIZATION;

D O I：

10.3389/fphar.2022.898718

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Arrhythmias are clinically prevalent with a high mortality rate. They impose a huge economic burden, thereby substantially affecting the quality of life. Sodium-glucose co-transporter 2 inhibitor (SGLT2i) is a new type of hypoglycemic drug, which can regulate blood glucose level safely and effectively. Additionally, it reduces the occurrence and progression of heart failure and cardiovascular events significantly. Recently, studies have found that SGLT2i can alleviate the occurrence and progression of cardiac arrhythmias; however, the exact mechanism remains unclear. In this review, we aimed to discuss and summarize new literature on different modes in which SGLT2i ameliorates the occurrence and development of cardiac arrhythmias.

引用

页数：12

共 155 条

[1] Association of fibrotic remodeling and cytokines/chemokines content in epicardial adipose tissue with atrial myocardial fibrosis in patients with atrial fibrillation [J].

Abe, Ichitaro ;

Teshima, Yasushi ;

Kondo, Hidekazu ;

Kaku, Haruka ;

Kira, Shintaro ;

Ikebe, Yuki ;

Saito, Shotaro ;

Fukui, Akira ;

Shinohara, Tetsuji ;

Yufu, Kunio ;

Nakagawa, Mikiko ;

Hijiya, Naoki ;

Moriyama, Masatsugu ;

Shimada, Tatsuo ;

Miyamoto, Shinji ;

Takahashi, Naohiko .

HEART RHYTHM, 2018, 15 (11) :1717-1727

[2] Ventricular pro-arrhythmic phenotype, arrhythmic substrate, ageing and mitochondrial dysfunction in peroxisome proliferator activated receptor-γ coactivator-1β deficient (Pgc-1β-/-) murine hearts [J].

Ahmad, Shiraz ;

Valli, Haseeb ;

Chadda, Karan R. ;

Cranley, James ;

Jeevaratnam, Kamalan ;

Huang, Christopher L. -H. .

MECHANISMS OF AGEING AND DEVELOPMENT, 2018, 173 :92-103

[3] Role of AMPK-mTOR-Ulk1/2 in the Regulation of Autophagy: Cross Talk, Shortcuts, and Feedbacks [J].

Alers, Sebastian ;

Loeffler, Antje S. ;

Wesselborg, Sebastian ;

Stork, Bjoern .

MOLECULAR AND CELLULAR BIOLOGY, 2012, 32 (01) :2-11

[4]

Altemose GT, 2001, CIRCULATION, V103, P762

[5] Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats [J].

Aragon-Herrera, Alana ;

Feijoo-Bandin, Sandra ;

Santiago, Manuel Otero ;

Barral, Luis ;

Campos-Toimil, Manuel ;

Gil-Longo, Jose ;

Pereira, Thiago M. Costa ;

Garcia-Caballero, Tomas ;

Rodriguez-Segade, Santiago ;

Rodriguez, Javier ;

Tarazon, Estefania ;

Rosello-Lleti, Esther ;

Portoles, Manuel ;

Gualillo, Oreste ;

Ramon Gonzalez-Juanatey, Jose ;

Lago, Francisca .

BIOCHEMICAL PHARMACOLOGY, 2019, 170

[6] Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy [J].

Arow, M. ;

Waldman, M. ;

Yadin, D. ;

Nudelman, V. ;

Shainberg, A. ;

Abraham, N. G. ;

Freimark, D. ;

Kornowski, R. ;

Aravot, D. ;

Hochhauser, E. ;

Arad, M. .

CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)

[7] Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status [J].

Asensio Lopez, Maria del Carmen ;

Lax, Antonio ;

Hernandez Vicente, Alvaro ;

Saura Guillen, Elena ;

Hernandez-Martinez, Antonio ;

Fernandez del Palacio, Maria Josefa ;

Bayes Genis, Andoni ;

Pascual Figal, Domingo A. .

SCIENTIFIC REPORTS, 2020, 10 (01)

[8] Zoniporide preserves left ventricular compliance during ventricular fibrillation and minimizes postresuscitation myocardial dysfunction through benefits on energy metabolism [J].

Ayoub, Iyad M. ;

Kolarova, Julieta D. ;

Kantola, Ronald L. ;

Radhakrishnan, Jeejabai ;

Wang, Sufen ;

Gamuri, Raul J. .

CRITICAL CARE MEDICINE, 2007, 35 (10) :2329-2336

[9] Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia [J].

Azam, Mohammed Ali ;

Chakraborty, Praloy ;

Si, Daoyuan ;

Du, BeiBei ;

Masse, Stephane ;

Lai, Patrick F. H. ;

Ha, Andrew C. T. ;

Nanthakumar, Kumaraswamy .

LIFE SCIENCES, 2021, 276

[10] Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits [J].

Baartscheer, Antonius ;

Schumacher, Cees A. ;

Wust, Rob C. I. ;

Fiolet, Jan W. T. ;

Stienen, Ger J. M. ;

Coronel, Ruben ;

Zuurbier, Coert J. .

DIABETOLOGIA, 2017, 60 (03) :568-573

← 1 2 3 4 5 6 7 8 9 10 →